Logo

Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia

Share this

Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia

Shots:

  • The P-III QUAZAR AML-001 study involves assessing of CC-486 (300mg) as maintenance therapy vs PBO + SoC in 472 patients in a ratio (1:1) with AML who achieved first CR with incomplete blood count recovery (CRi) with induction chemotherapy (with/out consolidation)
  • The P-III QUAZAR AML-001 study resulted in meeting its 1EPs & 2EPs i.e- improvement in OS & RFS- safety- tolerability- healthcare resource utilization and patient-reported outcomes per the FACIT-Fatigue Scale and EQ-5D questionnaire respectively
  • CC-486 is an analog of cytidine nucleoside- incorporated into DNA & RNA act by causing DNA hypomethylation and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow with its anticipated regulatory submissions in H1’20

Click here to­ read full press release/ article | Ref: Celgene | Image: Bio Online


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions